|
|
News Breaks
|
February 3, 2012
|
| 09:36 EDT |  | NVDL, APRI |
| theflyonthewall.com: | Apricus Biosciences acquires NitroMist rights outside N.A. from NovaDel | | Apricus Biosciences (APRI) announced the execution of a binding term sheet with NovaDel Pharma Inc. (NVDL) for the sale and license of rights in territories outside of the United States, Canada and Mexico to NovaDel's NitroMist, an FDA-approved nitrate vasodilator indicated for acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease. Apricus currently intends to file for approval of NitroMist in multiple international territories, including Europe. Under the term sheet for the Sale Agreement, Apricus Bio will acquire patents, patent applications, trademarks and trademark applications to NitroMist owned or controlled by NovaDel outside the U.S., Canada and Mexico including an exclusive, perpetual and royalty-free license to trade secrets and know how and to the rights to commercialize the product outside of North America. :theflyonthewall.com |
|
|
News For APRI;NVDL From The Last 14 Days Check below for free stories on APRI;NVDL the last two weeks.
There are 3 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
May 22, 2012
|
| 10:14 EDT | | APRI |
|
|
May 21, 2012
|
| 09:36 EDT | | APRI |
| theflyonthewall.com: | Apricus Biosciences granted regulatory meeting with FDA | | Apricus Biosciences announced that the FDA has granted the company's request for a Type C meeting to obtain regulatory guidance from the agency for Femprox, the company's topical alprostadil cream for the treatment for female sexual arousal disorder. The meeting is expected to take place in late July and the purpose of the meeting is to obtain feedback from the agency regarding the suitability of Femprox's clinical, preclinical, and quality control data to support a New Drug Approval in the U.S. Apricus Bio was recently granted a Pre-New Drug Submission meeting for Femprox with Health Canada which is expected to take place on July 17, and the company is also working with its European agents to conduct similar meetings with various European health agencies. :theflyonthewall.com |
|
|
May 11, 2012
|
| 09:56 EDT | | APRI |
| theflyonthewall.com: | Apricus Biosciences granted pre-NDS meeting for MycoVa | | Apricus Biosciences announced that Health Canada has granted the Company's request for a Pre-New Drug Submission meeting to obtain regulatory guidance from the agency for MycoVa, the Company's topical treatment for onychomycosis, or nail fungus. The meeting is scheduled to take place July 18, 2012. Apricus Bio expects to obtain feedback from Health Canada regarding the suitability of its Phase 3 development program to support a New Drug Submission in Canada. In addition, the Company is seeking guidance from the US Food and Drug Administration and will be filing for guidance from the European Health Agency. :theflyonthewall.com |
|
|
|
|
|
Subscribe for More Information